Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma Models.

ABSTRACT:

Background

Despite significant therapeutic progress, many lymphoma subtypes remain difficult to manage due to resistance, relapse, and dose-limiting toxicity.

Methods

To elucidate the mechanism of action of the semi-synthetic flavonoid derivative (SND) compounds, we conducted a screening of cancer cell lines using proliferation, cell cycle, and apoptosis assays. We then performed computational modeling of the compounds' binding to tubulin, and finally evaluated in vivo activity using nanoNail technology alongside xenograft experiment.

Results

Here, we describe a series of SNDs that exhibit low-nanomolar to picomolar cytotoxicity across multiple lymphoma models, including those resistant to BTK and PI3K inhibitors. Mechanistic studies show that these compounds trigger

SUBMITTER: Gaudio E 

PROVIDER: S-EPMC12177665 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature